Freedom Care Group Holdings saw revenue plummet 98% to $319,000 and cut its loss by over 90% to $347,000 for FY26 following the liquidation of key subsidiaries. The company is now exploring strategic options to revive operations and address liquidity challenges.
- Revenue collapses 98% to $319,000
- Loss narrows 91% to $347,000
- Key subsidiaries liquidated in January 2025
- Board exploring acquisitions and partnerships
- Cash reserves stand at $407,000 with material uncertainties
Revenue Collapse and Subsidiary Liquidation
Freedom Care Group Holdings Limited (ASX:FCG) reported a dramatic 98% plunge in revenue to just $319,000 for the year ended 30 June 2026, a stark contrast to the $15.8 million recorded in the prior year. This collapse stems from the loss of control over its principal operating subsidiaries, Freedom Care Group Pty Ltd and Regional Disability Services Group Pty Ltd, which were placed into liquidation in January 2025. Since then, Freedom Care has ceased trading activities, with the current financials primarily reflecting corporate, compliance, and legal costs.
Loss Significantly Reduced But Material Uncertainty Remains
The company’s loss after tax narrowed sharply by 91.3% to $347,000, compared to a $4 million loss in FY25. Basic earnings per share improved from a loss of 3.69 cents to 0.32 cents. Despite this improvement, the board flagged a material uncertainty regarding the group’s ability to continue as a going concern, citing ongoing liquidity pressures and the absence of operating revenue. Cash reserves stood at $407,000 at year-end, down slightly from $473,000 the previous year, while current liabilities exceeded current assets by $164,000.
Strategic Review and Potential Corporate Transactions
With its core operating subsidiaries in liquidation and no trading business, Freedom Care’s board is actively assessing strategic alternatives to leverage the company’s existing ASX-listed structure. Potential pathways include acquisitions, strategic partnerships, or corporate transactions that could enable the company to recommence operations and restore shareholder value. Among the opportunities under consideration is the Koala Disability Care Pty Ltd business, in which Freedom Care holds a 29% stake valued at $962,000. However, these discussions remain preliminary with no guarantee of successful execution or material financial improvement.
Ongoing Challenges: ASX Suspension and Legal Proceedings
Freedom Care’s securities have been suspended from trading on the ASX since late 2024 following the cessation of payments from the National Disability Insurance Agency (NDIA), which precipitated the liquidity crisis and subsidiary liquidations. The company faces the risk of delisting if suspension continues without resolution. Reinstatement would require compliance with ASX’s admission standards, a process with uncertain timing and outcome. Adding to the uncertainty, a shareholder has initiated legal action seeking access to company records, a matter currently before the courts.
Financial Position and Governance
Freedom Care’s balance sheet reflects the fallout from the liquidations, with net tangible assets per share declining to 0.74 cents from 1.06 cents. The company holds a director loan of $200,000, interest-free and repayable on demand but not expected to be called soon, providing some short-term liquidity support. Directors have not received remuneration during the year, underlining the company’s tight cost management. The auditor issued an unmodified opinion on the financial statements, despite the material uncertainty disclosures.
Freedom Care’s board remains unchanged, led by Non-Executive Chairman Zoran Grujic and Executive Director Jamal Sabsabi, who together hold a significant shareholding. The company continues to comply with its ASX continuous disclosure obligations while exploring ways to unlock value from its remaining assets and listed status.
Bottom Line?
Freedom Care’s FY26 results reveal a company in limbo, grappling with the aftermath of subsidiary liquidations and ASX suspension, while searching for a strategic lifeline to restore operations and investor confidence.
Questions in the middle?
- Will Freedom Care secure a viable acquisition or partnership to restart operations?
- How soon can the company resolve ASX suspension and avoid delisting?
- What impact will ongoing legal proceedings have on corporate governance and shareholder relations?